| Origin Energy Limited (ORG) ORDINARY FULLY PAID |
Utilities |
$20,604 |
December 2025 Quarterly Report
|
30 Jan 2026 8:28AM |
$11.800 |
$11.960 |
risen by
1.36%
|
|
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,426 |
2025 Full Year Results Release Date
|
30 Jan 2026 8:28AM |
$5.780 |
$5.200 |
fallen by
10.03%
|
|
| RMA Global Limited (RMY) ORDINARY FULLY PAID |
Communication Services |
$27 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:28AM |
$0.049 |
$0.041 |
fallen by
16.33%
|
|
RMY - Price-sensitive ASX Announcement
Full Release
Key Points
- Net operating cash outflow of $592,000 in Q2 FY26.
- Cash receipts from customers totaled $5.8 million, an 11% increase from Q2 FY25.
- Organic cash receipts grew by 3%, excluding Curated Social.
- Operational cash payments increased by 25% compared to Q2 FY25.
- RMA Global Limited rebranded to Renowned.
- US subscription revenue rose by 38% year-on-year.
- ANZ revenue grew by 5% due to new multi-year partnerships.
- Cash on hand as of 31 December 2025 was $3.1 million.
- Focus on expanding US market with multi-year brokerage deals.
- Payments to related parties totaled $114,000, related to director fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Felix Gold Limited (FXG) ORDINARY FULLY PAID |
Materials |
$124 |
Quarterly Activities and Cashflow Reports
|
30 Jan 2026 8:28AM |
$0.385 |
$0.250 |
fallen by
35.06%
|
|
FXG - Price-sensitive ASX Announcement
Full Release
Key Points
- $18 million institutional placement completed
- Blair Way appointed as Non-Executive Director
- Significant expenditure on exploration and project studies in Alaska
- Targeting metal production in H2 2026
- Submitted applications for DOE pilot processing facility and exploration technology
- Strengthened executive and non-executive governance
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NeuroScientific Biopharmaceuticals Ltd (NSB) ORDINARY FULLY PAID |
Health Care |
$35 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:27AM |
$0.135 |
$0.105 |
fallen by
22.22%
|
|
NSB - Price-sensitive ASX Announcement
Full Release
Key Points
- StemSmart™ Special Access Program for Crohn's Disease is advancing.
- Phase 2 Clinical Trial preparation is underway with real-world clinical data.
- Appointment of a Clinical & Scientific Advisory Board to support development.
- Technology transfer to Q-Gen for manufacturing readiness is progressing.
- Strong financial position with cash and cash equivalents approximately $6.4 million.
- Net cash outflow from operating activities was $532k for the quarter.
- Research and development payments totaled approximately $315k.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$224 |
Quarterly Activities and Cash Flow Reports - December 2025
|
30 Jan 2026 8:27AM |
$0.225 |
$0.820 |
risen by
264.44%
|
|
LOT - Price-sensitive ASX Announcement
Full Release
Key Points
- Kayelekera Uranium Mine's production impacted by sulphuric acid supply issues.
- Production resumed mid-January with the best run time since restart.
- Acid plant rebuild on schedule for March 2026 commissioning.
- Uranium deliveries and strategy focus on market-linked pricing.
- Successful metallurgical testwork at Letlhakane could reduce acid consumption by 70%.
- Closing cash balance A$56.2M, exploring additional financing options.
- No Lost Time Injuries recorded, targeting two million LTI-free person days.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$41,743 |
Dividend/Distribution - RMD
|
30 Jan 2026 8:27AM |
$36.400 |
$28.780 |
fallen by
20.93%
|
|
| Regis Healthcare Limited (REG) ORDINARY FULLY PAID |
Health Care |
$1,887 |
Initial Director's Interest Notice
|
30 Jan 2026 8:27AM |
$6.610 |
$6.240 |
fallen by
5.60%
|
|
| Far Limited (FAR) ORDINARY FULLY PAID |
Energy |
$57 |
Quarterly Activities Report and Appendix 5B
|
30 Jan 2026 8:27AM |
$0.455 |
$0.615 |
risen by
35.16%
|
|
FAR - Price-sensitive ASX Announcement
Full Release
Key Points
- FAR Limited reported a cash balance of US$1.9 million at the end of the December 2025 quarter.
- The company entered into a settlement agreement with Woodside Energy, paying US$6,029,899 concerning the RSSD Project claim.
- FAR Limited has a contingent payment agreement with Woodside Energy, which could give a maximum value of US$55 million, based on oil price and production conditions.
- The contingent payment is linked to the Sangomar Project in Senegal, and the payment terminates on the earliest of 31 December 2027 or when US$55 million is reached.
- The company has no outstanding loans or unused financing facilities as of the end of the quarter.
- Aggregate payments to related parties and their associates during the quarter were US$49,000, mainly for Non-Executive Director remuneration.
- The company forecasts having sufficient cash for 55.20 quarters based on current available funding and expenditures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Magnum Mining and Exploration Limited (MGU) ORDINARY FULLY PAID |
Materials |
$21 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 8:27AM |
$0.005 |
$0.007 |
risen by
30%
|
|
MGU - Price-sensitive ASX Announcement
Full Release
Key Points
- Commencement of two drilling programs at Palmares and Azimuth REE Projects.
- Acquisition of the Wet Mountains REE Project in Colorado.
- Leach testing at Feirinha Prospect confirmed high-value magnet feedstock potential.
- Oversubscribed A$7.0 million capital raise completed.
- Execution of binding MoU with HomeRun Resources for REE separation technology.
- Continued evaluation of a critical minerals processing hub in Nevada.
- Quarter-end cash and cash equivalents at $5.862 million.
- Estimated funding available for 4.97 quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Murray Cod Australia Limited (MCA) ORDINARY FULLY PAID |
Consumer Staple |
$18 |
Quarterly Activities/Appendix 4C Cash Flow Report - Q2 FY26
|
30 Jan 2026 8:27AM |
$1.045 |
$0.145 |
fallen by
86.12%
|
|
MCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Cash receipts from customers totaled $3,650,000 for Q2 FY26.
- Total cash outflows from operating activities amounted to $5,341,000.
- Sales volume increased but faced demand challenges for larger fish sizes.
- Net cash from financing activities was $6,162,000.
- MCA is expanding market presence in Southeast Asia.
- Company biomass reached 2,787 tonnes by the end of December 2025.
- Production infrastructure expansion is ongoing with full pond utilization expected.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$5,671 |
Update - Notification of buy-back - DNL
|
30 Jan 2026 8:26AM |
$3.560 |
$3.230 |
fallen by
9.27%
|
|
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$41,743 |
Resmed Announces Results for the Second Quarter of FY2026
|
30 Jan 2026 8:26AM |
$36.400 |
$28.780 |
fallen by
20.93%
|
|
RMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 11% to $1.422 billion.
- Non-GAAP gross profit margin improved to 62.3%.
- Net income rose to $392.6 million, an increase from $344.6 million.
- Diluted earnings per share increased to $2.68.
- Strong sales performance in U.S., Canada, and Latin America.
- Growth driven by devices and masks sales.
- Operational efficiency improved despite global challenges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Murray Cod Australia Limited (MCA) ORDINARY FULLY PAID |
Consumer Staple |
$18 |
Appointment of Non-Executive Director - Peter McCluskey
|
30 Jan 2026 8:26AM |
$1.045 |
$0.145 |
fallen by
86.12%
|
|
| Bannerman Energy Ltd (BMN) ORDINARY FULLY PAID |
Energy |
$804 |
Change in substantial holding - MMAM
|
30 Jan 2026 8:25AM |
$4.700 |
$3.870 |
fallen by
17.66%
|
|
| NewPeak Metals Limited (NPM) ORDINARY FULLY PAID |
Materials |
$5 |
Quarterly Activities and Cashflow Reports
|
30 Jan 2026 8:25AM |
$0.027 |
$0.015 |
fallen by
44.44%
|
|
NPM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash outflow from operating activities driven by staff and corporate costs.
- Investing activities include acquisition payments related to exploration permits.
- End of quarter cash position is approximately $2.49 million.
- Las Opeñas drilling approval significantly impacts future exploration plans.
- No exploration activities planned at George River and Treuer Range projects in the near term.
- Exploration Manager visited Cachi Gold Project; focus is shifting to Las Opeñas.
- Payments to related parties include executive and non-executive director fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fleetwood Limited (FWD) ORDINARY FULLY PAID |
Consumer Discretionary |
$152 |
Appointment of New Chief Executive Officer
|
30 Jan 2026 8:25AM |
$2.850 |
$1.640 |
fallen by
42.46%
|
|
FWD - Price-sensitive ASX Announcement
Full Release
Key Points
- Appointment of Andrea Pidcock as CEO effective February 2, 2026.
- Extensive leadership experience in industrial and operational sectors.
- Former executive roles at Rio Tinto, Optus, and Boral.
- Focus on EBIT improvement and operational enhancements.
- Andrea's leadership expected to drive growth in construction methods.
- Annual remuneration of $700,000 with incentive plans.
- Executive Chairman John Klepec to return as non-executive director.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
Quarterly Appendix 4C and Activities Report
|
30 Jan 2026 8:25AM |
$0.005 |
$0.004 |
fallen by
20%
|
|
1AD - Price-sensitive ASX Announcement
Full Release
Key Points
- AdAlta launched 'East to West' strategy with Shanghai Cell Therapy Group.
- Development of CAR-T therapy targeting mesothelioma.
- Raised $2.8 million through private placements.
- Received $0.93 million R&D Tax Incentive refund.
- Cash balance increased to $1.58 million by end of quarter.
- Significant expenditures in R&D and staff costs.
- Strengthened financial position with capital raises and repayments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$16,324 |
Notification regarding unquoted securities - JHX
|
30 Jan 2026 8:25AM |
$33.730 |
$28.130 |
fallen by
16.60%
|
|
| Proteomics International Laboratories Ltd (PIQ) ORDINARY FULLY PAID |
Health Care |
$40 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:25AM |
$0.570 |
$0.245 |
fallen by
57.02%
|
|
PIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Proteomics International Laboratories Ltd reported cash receipts from customers totaling $127,000 for the current quarter and $1,991,000 year-to-date.
- Research and development payments were $965,000 for the current quarter and $1,996,000 year-to-date.
- The company received government grants and tax incentives amounting to $2,687,000.
- There was a net cash outflow from operating activities of $182,000 for the quarter, and $951,000 year-to-date.
- Investing activities resulted in a net cash outflow of $1,986,000 for the current quarter and $2,059,000 year-to-date.
- Financing activities yielded a net cash outflow of $182,000 for the quarter and $358,000 year-to-date.
- Cash and cash equivalents decreased from $10,019,000 at the beginning of the quarter to $7,669,000 by the end.
- Payments to related parties during the quarter totaled $194,000, which relate to remuneration for Directors.
- The company has no loan facilities or credit standby arrangements available.
- Proteomics International Laboratories Ltd estimates 42 quarters of funding available with the current cash flow.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fluence Corporation Limited (FLC) ORDINARY FULLY PAID |
Utilities |
$93 |
Fluence Q4 2025 Update Investor Presentation
|
30 Jan 2026 8:25AM |
$0.089 |
$0.081 |
fallen by
8.99%
|
|
FLC - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong financial growth with Q4 and FY 2025 revenue of $26.0M and $78.4M, respectively.
- Significant backlog increase to $74.8M with core business units' backlog growing by 43.8%.
- Record new order bookings for Q4 2025 and FY 2025.
- Strategic shift to high-margin Smart Product Solutions and Recurring Revenue segments.
- Completion of CEO/CFO succession and strategic realignment.
- Notable projects in Ivory Coast, Saudi Arabia, Argentina, and Italy.
- Enhancements in Municipal Water & Wastewater and Industrial Wastewater & Biogas segments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Galilee Energy Limited (GLL) ORDINARY FULLY PAID |
Energy |
$11 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 8:25AM |
$0.009 |
$0.006 |
fallen by
33.33%
|
|
GLL - Price-sensitive ASX Announcement
Full Release
Key Points
- Acquisition of Zydeco Gas Project in Louisiana, USA.
- Successful A$6.5 million capital raise.
- Board restructured with Joseph Graham as Managing Director.
- Glenaras Gas Project wells offline, focus on reservoir monitoring.
- Cash position at $2.93 million by end of quarter.
- Springsure Project relinquished.
- Appendix 5B Cash Flow Report released.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WhiteHawk Limited (WHK) ORDINARY FULLY PAID |
Information Technology |
$7 |
Quarterly Activities Report and Appendix 4C
|
30 Jan 2026 8:25AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
WHK - Price-sensitive ASX Announcement
Full Release
Key Points
- WHK Team won US$246K Cyber Analyst PaaS Grant from Miami Dade County.
- Responded to State of Maryland Cyber Clinics RFP for a US$1M contract.
- Operationalized WHK APEC Office for a joint venture with Novera.
- Reported US$343K revenue receipts for the quarter.
- Managed monthly operating expenses at US$235K on average.
- Incurred US$364K in net cash outflows from operations.
- Established a dedicated APEC sales office in Australia.
- Explored strategic ventures including joint venture opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| TrivarX Ltd (TRI) ORDINARY FULLY PAID |
Health Care |
$30 |
December 2025 Quarterly Activities Report and Appendix 4C
|
30 Jan 2026 8:24AM |
$0.020 |
$0.026 |
risen by
30%
|
|
TRI - Price-sensitive ASX Announcement
Full Release
Key Points
- TrivarX completed a clinical trial to screen for Major Depressive Episode (cMDE) in veterans using a single-lead ECG algorithm.
- The trial, conducted with the US Veterans Affairs, showed high sensitivity and specificity, validating the ECG algorithm.
- TrivarX acquired Stabl-Im technology, expanding its portfolio into neuro-oncology imaging.
- The Stabl-Im platform uses MRI and stable isotope labelling for early detection of active tumour growth.
- Financial report shows cash at bank of $3.47m at the end of December 2025.
- Payments of $1,000 were made to related parties during the quarter.
- TrivarX secured $4.2 million in funding for advancing diagnostic platforms and development activities.
- John Mathias resigned as Non-Executive Director effective 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$410 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:24AM |
$0.260 |
$0.255 |
fallen by
1.92%
|
|
TTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Titomic maintained a cash position of AUD 35.8 million at December 2025.
- Anticipates increase in customer receipts and modest rise in operating expenses in 2026.
- Secured a USD 1.7 million defense contract and completed a hot fire test for Northrop Grumman.
- Expanded into semiconductor and energy sectors with new system deployments.
- Demonstrated cold spray technology for lithium-ion battery manufacturing.
- Deployed cold spray system for offshore Oil & Gas operations.
- Expanded global footprint with system sales in Portugal and the U.S.
- Targeting break-even cash flow by CY 2027, not needing further capital.
- Net cash used in operations was AUD 7.1 million.
- Net cash used in investing was AUD 3.8 million.
- Cash balance supports 5 quarters of funding availability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
